ITGB3 and nasopharyngeal carcinoma: We found that both P-EVs treatment and ITGB3 overexpression enhanced the migration of NPC cells, but ITGB3 knockout and treatment with cilengitide, an ITGB3 inhibitor, impaired the P-EVs-induced migration of NPC cells (Figure 2F).